← Oncology Approval Tracker

FDA DECISION ·

Hyrnuo

sevabertinib · Bayer

Accelerated approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic nonsquamous NSCLC with an activating HER2 (ERBB2) tyrosine kinase domain mutation on an FDA-authorized test. The expanded label removes the prior systemic-treatment requirement.

LAMPGEN ANALYSIS

Why it matters

The new label broadens an existing accelerated indication to include patients without prior systemic therapy. HER2 kinase-domain mutations define the population.

What research teams should watch

Reconcile HER2 mutation class, stage and earlier therapy in the screening record. Follow the confirmatory study and avoid equating response in a single-arm cohort with comparative survival benefit.

PRIMARY RECORDS

Sources